Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 4, 2026, reporting the election of directors (Kay M. Dorow and Steven Haen) and ratification of the independent auditor (Plante Moran, PLLC). The filing directly corresponds to Item 5.07 and presents final voting tallies for each matter submitted to stockholders, which is material to investors' understanding of corporate governance and audit oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 45%
filed 2026-06-05
Item 8.01
Uniti announced the pricing of $1,140.71 million in secured fiber network revenue term notes issued by subsidiary Kinetic ABS Issuer LLC, with expected closing on July 15, 2026. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the provided taxonomy—it is neither equity dilution (dilutive_issuance typically refers to equity securities) nor a standard M&A or financing event with a dedicated Item. The disclosure is material but the event type is ambiguous.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
LifeCore Biomedical held its Annual Meeting of Stockholders on June 4, 2026, with voting results on four proposals: election of nine directors, ratification of KPMG LLP as auditor, advisory approval of named executive officer compensation, and approval of the 2026 Stock Incentive Plan. All vote tallies (For, Against, Abstain, and Broker Non-Votes) are disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-05
Item 5.02
The filing discloses the appointment of Eric Palomaki, the Company's President & Chief Executive Officer, to the Board of Directors on June 5, 2026, to fill a vacancy created by David L. Duvall's resignation. While the section also includes details of an amended employment agreement with compensation terms, the principal disclosed action is Palomaki's appointment to the board. This is material as it involves a change in board composition and governance structure for the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
OneSpan held its 2026 annual meeting of stockholders on June 5, 2026, with shareholders voting on five proposals: election of seven directors, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, amendment to the 2019 Omnibus Incentive Plan to increase available shares by 2,000,000, and ratification of KPMG LLP as independent auditor. All five proposals passed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Netflix held its annual meeting of stockholders on June 4, 2026, with detailed vote results disclosed for the election of 12 directors, ratification of auditors, advisory vote on executive compensation, and four non-binding stockholder proposals.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-05
Item 8.01
The Board appointed Jay Hoag to serve as Chairman of the Board effective after the Annual Meeting, transitioning from his prior role as Lead Independent Director since 2012.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-05
Item 4.01
The Company terminated its independent registered public accounting firm, Hudgens CPA, PLLC, on June 2, 2026, after discovering that Hudgens had withdrawn from the PCAOB and ceased operations without notifying the Company. This is a clear auditor change under Item 4.01. The disclosure confirms no disagreements or reportable events occurred, indicating a clean termination driven by the auditor's withdrawal rather than audit quality concerns. The event is material as it affects the registrant's ability to file compliant financial statements and audit reports.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-05
Item 4.01
Assure CPA, LLC resigned as the Company's independent registered public accounting firm effective June 3, 2026, due to the sale of substantially all of Assure's assets to Sadler Gibb & Associates, LLC and Assure's cessation of operations. No disagreements on accounting principles, practices, or auditing scope were reported.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Lifeloc Technologies held its Annual Meeting of Shareholders on June 3, 2026, with voting results on four matters: election of five directors, ratification of independent auditor (Assure CPA), advisory vote on executive compensation, and approval of amended articles of incorporation.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-05
Item 7.01
The company issued a press release disclosing financial results for the third fiscal quarter ended April 30, 2026, furnished as Exhibit 99.1 under Regulation FD Disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-05
Item 2.02
G III Apparel Group disclosed results of operations for the first fiscal quarter ended April 30, 2026, furnished as a press release in Exhibit 99.1.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-05
Item 7.01
The company disclosed a previously announced transaction to acquire the Marc Jacobs operating business through a joint venture with WHP Global, with investor presentation materials furnished under Regulation FD.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
Hut 8 Corp. announced the pricing of a $4.25 billion senior secured debt offering by its subsidiary Beacon Point DC LLC. While this is a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the standard taxonomy categories (not an earnings release, M&A activity, impairment, or other specifically enumerated event types). The disclosure is material because a $4.25 billion debt issuance significantly impacts the registrant's financial position and obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-05
Item 2.02
The filing discloses results of operations for the second fiscal quarter and six months ended April 30, 2026, with the earnings release attached as Exhibit 99.1 and furnished pursuant to Item 2.02. This is a standard earnings release disclosure that would materially affect a reasonable investor's assessment of the company's financial performance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 filing discloses the results of Ur-Energy Inc.'s Annual General and Special Meeting of Shareholders held on June 4, 2026, including voting outcomes on five proposals: election of eight directors (all elected with high approval rates), reappointment of BDO USA as auditors, advisory votes on executive compensation and say-when-on-pay frequency, and renewal of the stock option plan. The detailed vote tallies and shareholder participation (70.84% quorum) are material to investors assessing governance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four matters: election of eight directors (all approved by majority), appointment of PricewaterhouseCoopers LLP as independent auditor (97.38% approval), an advisory vote on named executive officer compensation (33.72% approval, notably not approved), and approval of Amendment No. 5 to the 2016 Stock Plan (90.76% approval). The disclosure includes vote counts and percentages for each proposal, which is the standard format for shareholder vote results.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-05
The 8-K discloses the issuance of $500 million in 4.650% Senior Notes Due 2029 under an Underwriting Agreement dated June 1, 2026. While this is a debt issuance rather than equity, the filing exhibits an underwriting agreement and supplemental indenture for a material capital raise. The magnitude ($500M) and formal structure (registered offering via Form S-3) indicate a material financing event, though the debt nature makes it less clearly "dilutive" in the equity sense; however, it represents a material liability issuance that would affect investor assessment of the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-05
Item 8.01
The filing discloses a warrant inducement agreement requiring stockholder approval for the issuance of up to 16,184,560 shares of common stock upon warrant exercise. Although the Special Meeting failed to achieve quorum, the core material event is the company's obligation to seek approval for a substantial dilutive issuance of equity securities to institutional investors under the October 16, 2025 Inducement Agreement. This represents a material capital structure event affecting existing shareholders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-05
Item 8.01
The filing discloses the consummation of a business combination on June 5, 2026, whereby Cartesian Growth Corporation III (a SPAC) merged with Factorial Inc., with Factorial surviving as a wholly-owned subsidiary and CGC domesticating and rebranding as Factorial Energy Inc. This is a material change of control and merger transaction, evidenced by the domestication, merger of Merger Sub into Factorial, share conversions, redemptions, and the resulting company's listing on Nasdaq under new ticker symbols "FAC" and "FACWW."
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 disclosure reports the results of Westrock Coffee's 2026 annual meeting of stockholders held on June 5, 2026, including the election of four Class I directors (Mark A. Edmunds, Joe T. Ford, Kenneth M. Parent, and Oluwatoyin Umesiri) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly matches the shareholder_vote_results event type and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Omega Healthcare Investors held its 2026 Annual Meeting of Shareholders on June 5, 2026. Shareholders voted on and approved three proposals: election of eight directors, ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Ribbon Communications' annual meeting of stockholders held on June 3, 2026. The filing presents voting results for three proposals: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, representing routine shareholder governance matters that are material to investors' understanding of corporate governance and board composition.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-05
Item 5.02
The Board adopted a revised Director Compensation Policy effective June 4, 2026, modifying the structure of director compensation by splitting RSU awards equally between restricted stock units and a long-term cash award to reduce dilution.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Shareholders voted at the 2026 Annual Meeting of Stockholders held on June 4, 2026, approving the election of seven directors, the advisory approval of executive compensation, and the ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-05
Item 8.01
Duke Energy Carolinas consummated the issuance and sale of $2.4 billion in mortgage bonds across three series (4.65% due 2031, 5.15% due 2036, and 5.75% due 2056) on June 5, 2026. While this is a material debt financing event affecting the company's capital structure and financial position, it does not fit cleanly into the standard 8-K taxonomy categories. The disclosure is a straightforward debt issuance completion rather than a restatement, impairment, covenant breach, or other more specific event type, warranting classification as "other_material."
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-05
Item 8.01
Humacyte disclosed receipt of a Nasdaq deficiency notice on May 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), followed by notification on June 5, 2026, that the company had regained compliance. This disclosure directly addresses delisting risk and continued listing status, which is material to investors assessing the registrant's ability to remain publicly traded.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
The Company is winding down two material agreements (Native Markets Temporary Use Agreement and Felix Foundation HAUS Agreement) involving approximately $28.7 million in combined asset value as of March 31, 2026. While this involves repositioning of assets rather than a traditional M&A transaction, covenant breach, or other specifically-defined event type, the termination of these material agreements and the return of ~800,000 HYPE tokens represents a significant strategic shift that would affect a reasonable investor's assessment of the Company's operations and asset positioning.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-05
Item 3.02
The filing discloses an unregistered sale of 1,150,000 shares of common stock at $4.82 per share (approximately $5.5 million in gross proceeds) relying on Rule 506 exemption. This is a classic private placement to a sophisticated investor with restricted legend shares, representing a material dilutive issuance that would affect a reasonable investor's assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a clear disclosure of shareholder vote results from Ladder Capital's June 4, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: (1) re-election of Brian Harris and Mark Alexander as Class III Directors, and (2) ratification of Ernst & Young LLP as independent auditor for 2026. The detailed vote tallies (votes for, votes withheld/against, broker non-votes, and abstentions) are presented in tabular form, which is the standard format for Item 5.07 disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 4, 2026, covering three proposals: election of three Class II Directors (Laura Brege, Badreddin Edris, and Jonathan Root), ratification of KPMG LLP as independent auditor, and advisory vote on named executive officer compensation. The filing directly matches Item 5.07 requirements and presents final vote tallies for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Consolidated Water Co. Ltd. held its Annual General Meeting on June 1, 2026, at which shareholders voted on eight proposals including director elections, approval of the 2027 Employee Stock Incentive Plan, authorization of share capital increases, amendments to the Memorandum and Articles of Association, an advisory vote on executive compensation, and ratification of the independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-05
Item 8.01
Pinnacle West disclosed an amendment to an at-the-market (ATM) equity distribution agreement permitting the offer and sale of up to $900 million in common stock shares. While the First Amendment itself only modified the forward sale maturity period from 18 to 24 months, the underlying ATM program represents a material dilutive issuance mechanism. The company has already sold approximately $630 million of the authorized shares, with $270 million remaining available, indicating active use of this equity financing facility. This disclosure is material to investors assessing capital structure and shareholder dilution risk.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-05
Item 5.02
The Board approved grants of 7,000,000 restricted shares to four executives and directors (Silverman, Bernstein, Boctor, and Walker) with a two-tranche vesting schedule (50% immediate, 50% at six months). This is a compensatory arrangement for named executives and directors, clearly falling under Item 5.02(e) disclosure of equity grants. The aggregate size and broad distribution to senior leadership makes this material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-05
Item 1.01
Howard Hughes Insurance Holdings, LLC (a subsidiary of Howard Hughes Holdings Inc.) completed the acquisition of all outstanding shares of Vantage Group Holdings, Ltd. for $2.1 billion in cash on June 4, 2026. This material acquisition represents a significant capital deployment and business combination affecting the registrant's strategic position and financial condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-05
Item 3.02
Howard Hughes Holdings Inc. completed an unregistered sale of preferred stock under Section 4(a)(2) and Regulation D exemptions. The securities have not been and will not be registered under the U.S. Securities Act of 1933, representing a material private placement capital-raising event.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-05
Item 3.03
The filing discloses a material modification to the rights of security holders, specifically relating to preferred stock rights, in connection with the transactions described in the 8-K.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 disclosure reports the results of PTC Therapeutics' Annual Meeting held June 2, 2026, including election of four Class I directors, ratification of Ernst & Young LLP as independent auditor, and approval of a non-binding advisory vote on named executive officer compensation. The filing presents vote tallies for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 3.03
GPGI completed a reincorporation from Delaware to Nevada on June 5, 2026, materially modifying stockholder rights by changing the governing law and corporate charter. The reincorporation represents a significant corporate governance restructuring that affects the legal framework governing shareholder rights.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-05
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from nLIGHT's 2026 annual meeting held on June 5, 2026. The filing reports voting outcomes on three proposals: election of a Class II director (Geoffrey Moore), ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The compensation proposal notably failed, with 24.6 million votes against versus 15.8 million for—a material governance signal that would affect investor assessment of management alignment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-05
Item 1.01
Planet Labs entered into an Equity Distribution Agreement authorizing the sale of up to $1.5 billion of Class A common stock through an "at the market offering" program with multiple sales agents and forward purchasers. This is a material dilutive equity issuance that will increase share count and is a significant capital-raising activity for the company, disclosed under Item 1.01 as a material definitive agreement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 filing discloses the results of Navient Corporation's 2026 Annual Meeting of Shareholders held on June 4, 2026, including voting outcomes on four proposals: election of six directors, ratification of KPMG LLP as independent auditor, advisory approval of executive compensation, and say-on-pay frequency. The detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core disclosure, making this a textbook shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-05
Item 3.02
This is a classic private placement of unregistered equity securities. Cenntro issued 1,000,000 shares of common stock at $3.93 per share for approximately $3.93 million in gross proceeds, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration. The filing explicitly discloses the unregistered sale under Item 3.02, and the transaction closed on June 2, 2026. This is material as it represents significant dilution to existing shareholders and a material capital raise.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 3.03
The company effected a 1-for-20 reverse stock split on June 5, 2026, which was authorized by stockholders on April 29, 2026. This capital restructuring consolidates shares and adjusts exercise prices and share reserves, materially modifying the rights and economic interests of all security holders.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-05
Item 5.02
Carrie D'Andrea, Vice President of Clinical Operations, is ceasing employment effective June 5, 2026. While the disclosure also mentions severance benefits and a consulting agreement, the principal disclosed action is the departure of a named officer. The filing centers on her separation from the Company, making exec_departure the most salient classification, though the compensation elements (severance and consulting fee) are secondary to the departure itself.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 filing discloses the results of Prairie Operating Co.'s 2026 Annual Meeting of Stockholders held on June 3, 2026, including voting outcomes for two proposals: election of four directors (Richard N. Frommer, Jonathan Gray, Stephen Lee, and Erik Thoresen) and ratification of Deloitte & Touche LLP as the independent auditor. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core disclosure required by Item 5.07, making this a clear shareholder vote results event that is material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-05
Item 5.07
Stockholders approved a reverse stock split proposal at a Special Meeting held on June 1, 2026, with the Board authorized to implement a 1-for-2 to 1-for-25 reverse stock split ratio at its discretion. The Board subsequently approved and announced implementation of a 1-for-6 reverse stock split, effective June 12, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
Edesa Biotech disclosed favorable exploratory clinical data for paridiprubart showing a 32% relative reduction in 28-day mortality in AKI patients and a 23% relative reduction in MAKE30 incidence, presented at the ERA Congress. While this represents material clinical progress for a biotech company's lead candidate, the disclosure emphasizes these are exploratory, post-hoc analyses not prespecified in the statistical plan, with nominal p-values not adjusted for multiplicity and explicit caution that confirmatory studies would be required. This clinical milestone does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, restatement, or litigation), making it best classified as other_material given its potential significance to investors assessing the company's pipeline prospects.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 92%
filed 2026-06-05
Item 1.01
The Company disclosed anticipated defaults under its Credit Agreement, specifically failures to satisfy financial covenants (minimum liquidity and Collateral Coverage Ratio) and reporting obligations. The lenders granted a forbearance agreement through June 12, 2026, explicitly reserving all rights and remedies.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-05
Item 5.02
The Board approved an Employee Retention Program providing cash-based retention awards and nonqualified stock option grants to named executive officers, including CEO Douglas W. Campbell ($1.2M cash plus 190,600 options), CFO Jonathan Collins ($563K cash plus 45,380 options), COO Jamie Fischer ($531K cash plus 50,660 options), and Chief Accounting Officer Vickie D. Judy ($300K cash plus 16,336 options).
View raw filing on EDGAR →